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k@helse-Abstract Background: Preoperative histologic examination of tumour tissue is essential
when deciding if endometrial cancer surgery should include lymph node sampling. We
wanted to investigate if biomarkers could improve prediction of lymph node metastasis
and outcome.
Patients and methods: Curettage specimens from 832 endometrial carcinoma patients
prospectively recruited from 10 centres in the MoMaTEC trial (Molecular Markers in
Treatment of Endometrial Cancer) were investigated for hormone receptor and p53 status.
Results: Eighteen per cent of tumours were double negative for oestrogen- and progester-
one receptors (ER/PR loss), 24% overexpressed p53. Pathologic expression of all markers
correlated with nodal metastases, high FIGO (Federation International of Gynecology anded by Elsevier Ltd.
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3432 J. Trovik et al. / European Journal of Cancer 49 (2013) 3431–3441Obstetrics) stage, non-endometrioid histology, high grade and poor prognosis (all
P < 0.001). ER/PR loss independently predicted lymph node metastasis (odds ratios
(OR) 2.0, 95% conﬁdence interval (CI) 1.1–3.7) adjusted for preoperative curettage histol-
ogy and predicted poor disease-speciﬁc survival adjusted for age, FIGO stage, histologic
type, grade and myometrial inﬁltration (hazard ratio (HR) 2.3, 95% CI 1.4–3.9). For
lymph node negative endometrioid tumours, ER/PR loss inﬂuenced survival independent
of grade.
Conclusion: Double negative hormone receptor status in endometrial cancer curettage inde-
pendently predicts lymph node metastasis and poor prognosis in a prospective multicentre
setting. Implementing hormone receptor status to improve risk-stratiﬁcation for selecting
patients unlikely to beneﬁt from lymphadenectomy seems justiﬁed.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Verified Endometrial Cancer
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Fig. 1. Overview of patients and data available from the prospective
international multicentre Molecular Markers in Treatment in Endo-
metrial Cancer (MoMaTEC) trial with corresponding tables and
ﬁgures. IHC = immunohistochemistry, N = number of cases.1. Introduction
Endometrial cancer is the most common gynaecolog-
ic malignancy in industrialised countries. Fifteen to
twenty per cent of patients with presumed localised dis-
ease at primary treatment recur.1,2 Of all patients dying
from this disease, one third was initially classiﬁed as low
risk for recurrence.3 Contrasting breast cancer,4,5
improved knowledge of molecular alterations relevant
for prognostication and targeting therapies in endome-
trial cancer6,7 has not been systematically incorporated
to tailor therapy.8
Metastatic lymph nodes detected as part of staging
during primary surgery, identiﬁes patients with poor
prognosis.1,9 Routine lymph node sampling has not con-
ﬁrmed to contribute any survival beneﬁt in randomised
studies,10,11 but is associated with increased complica-
tion rates.11
Preoperative endometrial biopsy by pipelle or curet-
tage is the cornerstone in diagnostics of endometrial
cancer and the ﬁrst step of treatment algorithm planning
for primary surgical treatment.12 Still, ﬁnal risk stratiﬁ-
cation of early stage disease has, until recently,13 been
based on assessing histologic subtype, grade and depth
of myometrial inﬁltration in hysterectomy speci-
mens.9,12,14 Several retrospective studies support that
status for oestrogen receptor (ER), progesterone recep-
tor (PR) and the tumour suppressor p53 in primary
tumours are independent prognostic markers.8 This
knowledge has not been systematically studied for
implementation of individualised surgical therapy in
endometrial cancer.10,11 Instead, the treatment algo-
rithm has moved towards more aggressive surgery
including pelvic and para-aortic lymphadenectomy,15,16
despite lack of established criteria and measures for
reproducibility, sensitivity and negative predictive value
for the procedure.17 Systematic clinical implementation
studies of biomarkers potential useful in surgically
staged endometrial cancer patients have been called for.8
On this background, we have investigated if assess-
ment of ER, PR and p53 in endometrial biopsies, could
improve preoperative identiﬁcation of patients with
lymph node metastasis and poor prognosis in theprospective international multicentre trial MoMaTEC
(Molecular Markers in Treatment of Endometrial
Cancer).182. Materials and methods
In total, 1192 consenting endometrial carcinoma
patients, have been prospectively recruited from 10 cen-
tres for collection of curettage specimens and clinical
information between May 2001 through 2010 as previ-
ously reported and summarised in Fig. 1.18 Distribution
of clinicopathologic data is listed in Table 1. Histologic
diagnosis from the routine pathology report and local
tumour boards from each centre were utilised. Preoper-
ative curettage histology reports, available for 1166
patients, were classiﬁed as low- versus high-risk; the lat-
ter including endometrioid grade 3, serous, clear cell,
carcinosarcoma and undiﬀerentiated subtypes. The 853
cases preoperatively classiﬁed as low-risk included 795
endometrioid grade 1 or 2 tumours and 58 hyperplasias
with or without atypia or other, benign diagnoses later
conﬁrmed as endometrial carcinoma in hysterectomy
specimens. Grading was performed both on the curet-
tage and hysterectomy specimen according to World
Health Organization (WHO) classiﬁcation, based on
Table 1
Characteristics at primary treatment of 1192 endometrial cancer
patients included in the MoMaTEC* trial.
Characteristics N %
Mean age (years) 66
Range 28–94
Menopausal status
Pre-/perimenopausal 120 10
Postmenopausal 1072 90
FIGO 2009 classiﬁcation stage
I 919 77
II 84 7
III 133 11
IV 56 5
Histological subtypea
Endometrioid 954 80
Adenosquamous 13 1
Clear cell 46 4
Serous 107 9
Carcinosarcoma 54 5
Undiﬀerentiated 18 2
Histological diﬀerentiationa,b,c
Grade 1 458 39
Grade 2 343 29
Grade 3 143 32
Primary surgery
Hysterectomy and oophorectomy 1147 96
Diagnostic curettage only 38 3
Palliative surgery 7 1
Lymph node sampling
Performed 856 72
Not performed 336 28
Additional treatmentd
None 801 70
Radiation 134 12
Chemotherapy 151 13
Chemo radiation 56 5
Hormonal treatment 5 1
Status at last follow-upe
Alive without disease 889 75
Alive with recurrent disease 89 8
Dead without disease 54 5
Dead with but not due to disease 13 1
Dead due to endometrial cancer 144 12
* MoMaTEC: Molecular Markers for Treatment of Endometrial
Cancer http://www.clinicaltrials.gov/ct2/show/NCT00598845.
a Based on evaluation of hysterectomy specimen.
b Missing data in 10 cases.
c Data pertaining to endometrioid subtype only.
d One thousand one hundred and forty-seven patients subjected to
hysterectomy and oophorectomy included.
e Data available for 1189 patients, N = number of patients.
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endometrioid tumours were all considered as high
grade.19
Pelvic lymph node sampling up to the aorta bifurca-
tion was performed as part of surgical staging in 72%
of the patients (n = 856). Para-aortic sampling was
done if suspicious nodes were encountered during theoperation. Median number of nodes removed was 14
(range 1–72), 10 or more lymph nodes were harvested
in 625 (73%), and 105 (12%) had metastatic lymph nodes.
The responsible surgeon, blinded for the biomarker
study results, decided the extent of sampling, balancing
preoperatively known histologic risk factors and the
patient’s co-morbidity. The patient group without
lymph node sampling was signiﬁcantly older with more
superﬁcial myometrial inﬁltration; otherwise not diﬀer-
ent from the sampled group (Supplementary Table 1).
Additional systemic treatment was given to 346
patients (30%), including nearly all patients with FIGO
(Federation International of Gynecology and Obstet-
rics) stages III and IV and half of patients with less
advanced stages with endometrioid grade 3 or non-
endometrioid subtypes.
Follow-up information regarding recurrence and sur-
vival was retrieved as previously reported.13 Date of last
follow-up was December 10th 2012 with mean and med-
ian follow-up time for survivors 39 and 38 months
(range 0–96). One hundred and forty-four patients died
from endometrial carcinoma.
Curettage samples were suﬃcient for biomarker anal-
yses in 832 women (70%). These were more often endo-
metrioid compared to non-endometrioid (84% versus
76%, P = 0.001) and diﬀerentiated (grade 1–2, 71% ver-
sus grade 3, 64%, P = 0.017) as compared to tumours
with insuﬃcient tissue available. Otherwise patient and
tumour characteristics (Supplementary Table 2) as well
as disease-speciﬁc survival (log-rank test P = 0.476)
were similar.2.1. Immunohistochemistry and tissue microarray (TMA)
TMAs consisting of triplets from each patient’s curet-
tage sample were prepared as described and validated
earlier.20,21 Microwave antigen retrieval (750 W for 10
and 350 W for 15 min) in Tris–EDTA buﬀer pH 9 before
using DAKO Autostainer (No 3400-9567), peroxidase
blocking (Dako S-2032) for 5 min. and incubating with:
Oestrogen Receptor a (ER) (Dako M7047) diluted 1:50,
Progesterone Receptor (PR) (Dako M3569) diluted
1:150 both for 30 min, and tumour protein 53 (p53)
(Dako M7001) diluted 1:1000 for 60 min. The EnVi-
sion+Mouse HRP labelled polymer secondary antibody
with DAB+ (K4006) was used. Slides were counter-
stained with Dako Automation Haematoxylin.202.2. Evaluation of staining
Blinded for patient characteristics and outcome,
slides were evaluated by two authors (J.T. and H.B.S.)
using a standard light microscope. Nuclear staining
was scored using a semi-quantitative staining index
(range 0–9) as product of staining intensity (score 0–3)
and tumour area staining positive (0 = no staining,
3434 J. Trovik et al. / European Journal of Cancer 49 (2013) 3431–34411 6 10%, 2 = 10–50% and 3 > 50%), described ear-
lier.20,22,23 In line with the former study,20 lower quartile
of the dataset was applied as cut-oﬀ corresponding to
staining index 63 for ER and 0 for PR. Pathologic
expression of p53 (high) was deﬁned as upper quartile
(staining index P4) in line with previous reports.23,24
Inter-observer reproducibility was evaluated re-scoring
random slides blinded for previous scoring, for 97, 104
and 76 patients respectively, yielding Kappa values of
0.91 for ER, 0.88 for PR and 0.86 for p53 stainings.
2.3. Statistical analyses
Assessing the immuno-markers’ predictive value for
lymph node metastasis was the primary objective, and
the prognostic impact the secondary objective of the
study. Disease-speciﬁc survival was deﬁned as time from
surgery to death from endometrial carcinoma. Living
patients were censored at last follow-up. Recurrence-
free survival was deﬁned as time from surgery to relapse
for patients considered cured by primary treatment. Sta-
tistical analyses were performed with IBM SPSS 20 pro-
gram (Statistical Product and Service Solutions version
20.0, IBM, New York) using Pearson’s chi-square test
exploring associations between categorical variables
and binary logistic regression to estimate odds ratios
(OR) for lymph node metastasis. Analysis of recur-
rence-free survival and disease-speciﬁc survival wasTable 2
Lymph node status in 605 endometrial cancer patients in the Molecular Ma
to lymphadenectomy in relation to clinicopathological variables and expre
Variables
Age
<66 years
P66 years
Histological type
Endometrioid
Non-endometrioid
Histological diﬀerentiationc
Grade 1–2
Grade 3
Myometrial inﬁltrationd
<50%
P50%
Oestrogen Receptor (ER)/Progesterone Receptor (PR)
Normal
Losse
p53
Normal
Pathological
a Lymph node negative (LNneg): 527 patients (87%).
b Lymph node positive (LNpos): 78 women (13%) with histologically co
c Data available for N = 603.
d Data available for N = 549.
e Loss of both ER and PR expression, N = number of patients.performed by Kaplan–Meyer method and compared
using Mantel–Cox (log-rank) test and Cox’ proportional
hazard method, adjusting for multiple baseline charac-
teristics found signiﬁcant in the univariate model as pre-
viously reported.23 We tested for potential interactions
between variables and examined that hazard functions
were proportional over time by log–log plots. All statis-
tical tests were two-sided and considered signiﬁcant if
P < 0.05. Power calculation was done as described in
earlier publication regarding the MoMaTEC Trial.25
2.4. Approvals
Norwegian Data Inspectorate (961478-2), Norwegian
Social Science Data Services (15501) and the local Institu-
tional Review Board (REKIII No. 052.01) approved the
MoMaTEC study registered at Clinical Trials (http://
www.clinicaltrials.gov/ct2/show/NCT00598845)18 and
prepared in accordance with STROBE26 and REMARK
recommendations.27
3. Results
3.1. Metastatic lymph nodes associate with pathologic
expression of curettage biomarkers
Presence of metastatic lymph nodes was signiﬁcantly
associated with histologic features known to correlaterkers in Treatment in Endometrial Cancer (MoMaTEC) trial subjected
ssion of biomarkers evaluated by Pearson’s chi-square test.
LNnega LNposb P
N (%) N (%)
0.583
281 (88) 39 (12)
246 (86) 39 (14)
<0.001
450 (90) 51 (10)
77 (74) 27 (26)
<0.001
387 (92) 36 (9)
138 (76) 42 (24)
<0.001
351 (98) 7 (2)
145 (77) 46 (23)
<0.001
443 (90) 49 (10)
84 (74) 29 (26)
0.001
408 (90) 47 (10)
119 (79) 31 (21)
nﬁrmed metastasis to P1 lymph nodes.
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grade 3 and deep myometrial inﬁltration (Table 2). All
three investigated biomarkers showed mainly nuclear
staining (Fig. 2). Loss of oestrogen receptor (ER-) stain-
ing (as opposed to positive staining in normal endome-
trium) was seen in 200 of 832 evaluable patient
samples (24%), progesterone receptor loss (PR-) in 197
(24%) and loss of both receptors (ER-/PR-) in 151
(18%). Pathologic (high) expression of p53 was demon-
strated in 197 patients (24%). Pathologic expression of
all three markers was signiﬁcantly associated with high
age at diagnosis, advanced FIGO stage, lymph node
metastasis, non-endometrioid histology and grade 3.
Double negative ER/PR correlated with deep myome-
trial inﬁltration (Supplementary Table 3). Evaluating
complete negative p53 (staining index = 0) as a separate
category, complete loss of p53 expression turned out as
an intermediate group, between low (Index 1–3) or high
(Index P4) demonstrated in Supplementary Table 3.
Percentage of lymph node metastasis was not signiﬁ-
cantly diﬀerent between negative (8.5%) and low
(10.6%, P = 0.616).
The hormone receptor stainings in curettage speci-
mens were compared to stainings from n = 364Fig. 2. Representative photomicrographs of immunohistochemical staining
(PR) and p53; ER normal (A), ER loss (B), PR normal (C), PR loss (D), p5
histology of tumour A and C–F were endometrioid, B was serous.corresponding hysterectomy TMA specimens. The
correlations were highly signiﬁcant, all P < 0.001
(chi-square test), ER 84% accuracy and PR 88%.
ER/PR had 89% accuracy (Supplementary Table 3).
3.2. Loss of ER and PR expression independently predicts
lymph node metastasis
High-risk histology in curettage, loss of ER/PR and
pathologic expression of p53, all predicted presence of
metastatic lymph nodes in a univariate model (Table 3).
26% of patients (29 of 113) with combined loss of ER/
PR expression had lymph node metastasis. Double loss
of hormone receptors was stronger than p53 in predict-
ing metastatic nodes with OR 3.12 (95% CI 1.87–5.22,
P < 0.001). When adjusting for preoperative histology,
p53 lost its predictive value, in contrast to ER-/PR-
status being an independent predictor for lymph node
metastasis with adjusted OR 2.04 (95% CI 1.12–3.70,
P = 0.02, Table 3). Using the three category p53 vari-
able (negative, low, high) in the logistic regression
regarding lymph node metastasis did not alter the con-
clusion; p53 was not a signiﬁcant factor while ERPR
loss still had independent OR 2.1 with P = 0.018. Fors for estimation of Oestrogen Receptor a (ER), Progesterone Receptor
3 normal (E), and p53 pathologic (F), each bar represent 20 lm. Final
Table 3
Prediction of lymph node metastasis based on conventional curettage histology and new biomarkers for 605 lymph node sampled endometrial
cancer patients in the Molecular Markers in Treatment in Endometrial Cancer (MoMaTEC) trial.
Variable Na Uni-
variate
odds ratios
(OR)
95%
conﬁdence
interval
(CI)
P Multi-
variate
OR
95%
CI
P Sensitivity Speciﬁcity Positive
predictive
value
Negative
predictive
value
All patients
Curettage histology <0.001 0.016 0.43 0.80 0.24 0.91
Low-riskb 465 1 1
High-riskc 140 3.07 1.87–5.04 2.07 1.14–
3.75
Oestrogen Receptor
(ER)/Progesterone
Receptor (PR)
expression
<0.001 0.020 0.37 0.84 0.26 0.90
Normal 492 1 1
Lossd 113 3.12 1.87–5.22 2.04 1.12–
3.70
p53 expression 0.001 0.438 0.40 0.77 0.21 0.90
Normal 455 1 1
Pathological 150 2.26 1.38–3.72 1.26 0.70–
2.27
Low-risk patients
By curettage histologyb
ER/PR expression 0.014 0.015 0.20 0.91 0.20 0.92
Normal 420 1 – 1 –
Lossd 45 2.75 1.23–6.17 2.89 1.23–
6.78
P53 expression 0.766 0.721 0.16 0.86 0.10 0.91
Normal 398 1 – 1
Pathological 67 1.14 0.49–2.67 0.85 0.34–
2.11
CurRisk & ER/PR
expression
Low-riskb & ER/PR
normal
420 1
High-risk &/or ER/PR
losse
185 3.33 2.05–5.42 <0.001 0.56 0.73 0.23 0.92
a N = 605 patients with data available for all variables included in uni- and multivariate logistic regression analysis.
b CurLow-risk: Benign, hyperplasia, endometrioid grade 1–2, N = 465.
c CurHigh-risk: Serous, clear cell, carcinosarcoma, undiﬀerentiated carcinomas, endometrioid grade 3.
d Patients with double loss of ER/PR expression.
e Fifty-seven patients with curettage histology low risk had ER/PR loss and their ﬁnal histology were Endometrioid (N = 47), adenosquamous
(N = 1), clear cell (N = 4), serous (N = 4) undiﬀerentiated (N = 1).
3436 J. Trovik et al. / European Journal of Cancer 49 (2013) 3431–3441patients presumed as low-risk based on preoperative his-
tology, loss of ER/PR expression predicted lymph node
metastasis with adjusted OR 2.89 (95% CI 1.23–6.78,
P = 0.015). Combining hormone receptor status and
preoperative histology, prediction of metastatic nodes
improved: The frequency of metastatic nodes was 8%
for low-risk (ER/PR normal and low risk histology),
and 23% for patients with either ER/PR loss or high-
risk curettage histology with OR 3.33 (95% CI 2.05–
5.42), P < 0.001, Table 3). Thus selecting for lymph
node sampling if either preoperative histology is high
risk or hormone receptor staining is negative will
increase the sensitivity of detecting metastatic nodes to
0.56 (from 0.43 curettage or 0.37 ER/PR loss if used sep-
arately, Table 3).Number nodes sampled correlated with detection of
metastatic lymph nodes with an OR 1.04 (95% CI
1.02–1.06) tested as logistic regression. However when
adding number of lymph nodes as a factor in the multi-
variate logistic regression model the OR of ER/PR sta-
tus is still a signiﬁcant independent predictor of
metastatic lymph nodes with OR 2.2, P = 0.011. Inter-
estingly, OR for curettage risk group based on histology
was weakened when adjusted for number of nodes in the
model with OR 1.8, 95% CI 0.97–3.3.
In selecting for lymph node sampling or not the his-
tology or grade was not signiﬁcantly diﬀerent (Supple-
mentary Table 2) but when sampling was performed
patients with high risk histology had signiﬁcantly more
lymph nodes sampled (P = 0.004 chi-square test, using
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P < 0.0013.3. Loss of hormone receptors independently predicts
poor outcome
Pathologic p53 expression and loss of ER/PR expres-
sion, signiﬁcantly predicted poor disease-speciﬁc sur-
vival (Supplementary Table 4, Fig. 3B and C), along
with high age, non-endometrioid histology, high grade,
high FIGO stage, deep myometrial inﬁltration and met-
astatic lymph nodes. There was 14% discrepancy
between preoperative and hysterectomy based histologic
risk group classiﬁcation, with 79 changing to high-risk
versus 35 changing to low-risk based on hysterectomy
evaluation. Preoperative high risk histology identiﬁed
patients with poor prognosis (Fig. 3A). A combination
of preoperative histology and ER/PR status further
reﬁned the identiﬁcation of poor survivors (Fig. 3D).
Double negative ER/PR showed independent prog-
nostic impact in Cox survival analysis, adjusted for
age, FIGO stage, myometrial inﬁltration, histologic sub-
type and grade assessed in hysterectomy specimens, with
hazard ratio (HR) 2.28 (95% CI 1.35–3.86, P = 0.002,
Table 4). p53 lost its independent prognostic impact in
this multivariate model. Incorporating p53 as three cat-
egories (negative, low, high) in the Cox multivariate
model did not alter the conclusion: p53 was not statisti-
cal independently signiﬁcant while ERPR negativity
retained HR 2.19 (95% CI 1.29–3.74, P = 0.004).
Interestingly, ER/PR status improved prediction of
survival also within prognostic subgroups deﬁned by
lymphadenectomy (Fig. 4). In stratiﬁed multivariate
analysis among patients without lymph node sampling,
double negative ER/PR status predicted poor outcome
with HR 4.15 (95% CI 1.60–10.77, P = 0.003) adjusted
for age, FIGO stage, myometrial inﬁltration, histologic
subtype and grade. Also for the lymph node negative
endometrioid subgroup, ER/PR negative status inﬂu-
enced survival independently of tumour grade with
HR 5.36 (95% CI 1.32–21.73, P = 0.019). For endome-
trioid grade 1–2 patients, a subgroup considered low
risk for recurrence; double negative ER/PR was an inde-
pendent and signiﬁcant predictor of poor recurrence-
free survival with HR 2.80 (95% CI 1.50–5.36,
P = 0.002) adjusted for FIGO stage and age.Fig. 3. Disease-speciﬁc univariate survival for endometrial carcinoma
patients according to preoperative low risk (endometrioid grade 1–2)
versus high risk histology (endometrioid grade 3/non-endometrioid
subtypes) (A), Oestrogen Receptor (ER)/Progesterone Receptor (PR)
expression (B), p53 expression (C), and combination of preoperative
histology and ER/PR expression; Low risk: Curettage histology and ER/
PR both low risk, Intermediate risk: Curettage histology or ER/PR high
risk, High risk: Curettage histology and ER/PR both high risk (D).4. Discussion
We report for the ﬁrst time in a large prospective
multicentre setting, that hormone receptor loss in preop-
erative endometrial carcinoma biopsies independently
Table 4
Multivariate survival analysis of endometrial cancer patients in the Molecular Markers in Treatment in Endometrial Cancer (MoMaTEC) trial
according to Cox’ proportional hazards regression model.
Variable Na Unadjusted
hazard ratio (HR)
95% conﬁdence
interval (CI)
P Adjusted
HR
95% CI P
Age 734 1.06 1.03–1.08 <0.001 104 1.02–1.07 0.001
FIGO stage <0.001 <0.001
I–II 661 1 – 1 –
III–IV 73 10.44 6.54–16.65 5.13 3.07–8.57
Myometrial inﬁltration <0.001 <0.001
<50% 485 1 – 1 –
>50% 249 4.61 2.81–7.57 3.11 1.81–5.36
Histological typeb <0.001 0.002
Endometrioid 635 1 1 –
Non-endometrioid 99 5.77 3.61–9.23 3.42 1.67–7.01
Histological gradeb <0.001 0.646
Grade 1–2 546 1 – 1 –
Grade 3 188 4.66 2.92–7.45 1.19 0.57–2.46
Oestrogen Receptor (ER)/Progesterone
Receptor (PR)
<0.001 0.002
Normal 614 1 – 1 –
Lossc 120 4.89 3.07–7.78 2.28 1.35–3.86
p53 <0.001 0.531
Normal 573 1 – 1 –
Pathological 161 3.54 2.23–5.62 0.81 0.42–1.56
a N = 734 for cases with data available for all variables included in uni- and multivariate analyses.
b Based on evaluation of hysterectomy specimen.
c Patients with double loss of ER/PR expression.
3438 J. Trovik et al. / European Journal of Cancer 49 (2013) 3431–3441and in addition to preoperative histology, predicts
lymph node metastasis.
Lymph node sampling is widely advocated as a com-
pulsory part of complete surgical staging, in particular
for intermediate- and high-risk endometrial cancer.12,16
No randomised trials have demonstrated any survival
beneﬁt from lymphadenectomy,10,11,28 a procedure asso-
ciated with prolonged operation time and increased
complication rate11 in an obese and co-morbid patient
population.12 Due to the relatively low frequency of
lymph node metastasis and recurrence in low-risk
groups, adequately powered randomised surgical trials
have been diﬃcult to conduct. Improved tools identify-
ing patients with high risk for lymph node metastasis
would reduce the required sample size in a randomised
clinical trial of lymphadenectomy, while avoiding poten-
tial unnecessary side eﬀects from sampling low-risk
patients. Standard preoperative histology carefully
assessed to identify patients with high and low risk for
aggressive disease should always be the ﬁrst step in a
treatment algorithm. But by applying a combination
of preoperative histology and ER/PR status in curet-
tage, we were able to deﬁne 69% of the patients as
low-risk with only 8% risk of lymph node metastasis
but 95% 5-year disease speciﬁc survival.
Non-endometrioid subtypes, endometrioid grade 3
and deep myometrial inﬁltration in the excised uterus
have consistently demonstrated to predict lymph node
metastasis,1,29 in line with our ﬁndings. Several methodsevaluating myometrial inﬁltration pre- or perioperative-
ly exist, with variation in reported accuracy for detec-
tion of deep inﬁltration; ranging from 67% to 84% for
vaginal ultrasound,30,31 47% to 100% for MRI,32 87%
for gross intra-operative inspection30 and perioperative
frozen section evaluation.33
The 14% discrepancy of preoperative versus ﬁnal his-
tologic subtype and grade in our study, when dichoto-
mised as high- versus low-risk, is well in line with
others ranging from 15% to 32%.33–35 Assessment of his-
tologic type and grade in preoperative specimens is con-
sidered less reliable compared to hysterectomy
evaluation, and 31% veriﬁed as high-risk patients based
on hysterectomy histopathology was missed preopera-
tively, illustrating the clinical need for improved tools
identifying high-risk cases. Tumour tissue in curettage
specimens/preoperative oﬃce biopsies are normally
more scant than tumour tissue available for evaluation
from the removed uterus. Still the sample size available
is unlikely to be the whole explanation for this discrep-
ancy as we found and report in Supplementary Table 2,
that the percentage of discordant histologic diagnose
(10% change between endometrioid or non-endometri-
oid histologic type, 14% change between low or high-
risk histology (incorporating grade)) was not signiﬁ-
cantly diﬀerent whether tissue were successfully
retrieved for TMA for further immunohistochemistry
analysis (n = 832) or unsuccessfully retrieved for TMA
preparation (n = 360), the latter considered a surrogate
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Lymph nodes 3 categories
Number at risk
LN negative
LN missing
LN positive
Number at risk
ER/PR normal
ER/PR loss
C
B
A
D
Lymph node negative patients 
Patients without lymph node sampling 
Number at risk
ER/PR normal
ER/PR loss
Lymph node positive patients 
Number at risk
ER/PR normal
ER/PR loss
Follow-up time (months)
189  163        135        88       44       32
  38    22   18        13         3         2
 49   44         35          17         11          5
 29   18  12     8           3          2
P < 0.001
P < 0.001
P < 0.001
P = 0.013
Fig. 4. Disease-speciﬁc univariate survival for endometrial carcinoma
patients according to lymph node status (A), Oestrogen Receptor
(ER)/Progesterone Receptor (PR) expression stratiﬁed for lymph node
status; lymph nodes negative (LNneg) patients (B), not lymph node
sampled (LNmissing) patients (C), positive lymph node (LNpos)
patients (D).
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tively collected tissue.
We have previously reported36 that discordant histol-
ogy in preoperative and post-operative assessments rep-
resent a group of patients with a distinct survival/
prognosis, signiﬁcantly diﬀerent from and intermediate
between those with concordant low risk curettage and
hysterectomy histology and those with concordant high
risk features. This may be related to tumour heterogene-
ity. Curettage specimens, investigated in this study,
probably reﬂect mostly the part of tumour protruding
in the uterine cavity. Deeper parts of the tumour may
have diﬀerent histologic and molecular ﬁndings that will
not necessarily be reﬂected in curettage specimens.
Although tumour heterogeneity has not been systemati-
cally studied, data regarding correlation between discor-
dant and concordant histology assessments and the
immunohistochemical biomarkers (Supplementary
Table 3) demonstrate that pathologic biomarker expres-
sions are signiﬁcantly higher in the group with discor-
dant histology. This also suggests that biomarkers may
aid in identifying this group of patients with poorer
prognosis.
Receptor status and p53 expression have been evalu-
ated as signiﬁcant predictors of endometrial cancer sur-
vival in several retrospective studies.37 A case–control
study investigating curettings from 76 patients found
p53 as independent predictor of metastatic nodes.38
ER or PR status, not determined in their study, was a
stronger predictor of lymph node metastasis and prog-
nosis in our larger prospective study. Immunohisto-
chemical expression of ER, PR and p53 has been
evaluated in retrospective series to correlate well
between curettage and ﬁnal hysterectomy specimen,20,24
supporting preoperative staining as representative for
status in tumour. Also in our series the hormone recep-
tor status correlated well between curettage and hyster-
ectomy specimens. The correlation for hormone
receptor status in full sections versus TMA has earlier
been studied comprehensively for breast cancer speci-
mens, demonstrating a good concordance of 97% for
ER staining and 98% for PR staining.39
Of particular clinical relevance is our ﬁnding that
double negative ER/PR signiﬁcantly adds predictive
and prognostic information for patients in the lowest
risk group; with endometrioid grade 1 or 2 tumours sub-
jected to lymphadenectomy, and also for patients with-
out lymph node sampling, thus providing important
information when addressing need for adjuvant therapy.
When evaluating cut-points, using lower quartiles,
this corresponded to staining index 0–3 for ER and 0
for PR. The same cut-oﬀs have been found in earlier
data sets published from our group.20,24 In breast cancer
where receptor negativity has been incorporated in
treatment algorithms for several years there are large
studies using 10% of cells staining positive as upper lim-
3440 J. Trovik et al. / European Journal of Cancer 49 (2013) 3431–3441its for receptor negativity, which would correspond with
staining index 3 (strong staining in less than 10%).40
Thus further studies for standardization of assessments
and cut points for new endometrial cancer biomarkers
for implementation in the clinic will be important.
Contrasting the treatment algorithms for breast can-
cer,4 and despite several studies demonstrating a strong
link between hormone receptor status and clinical phe-
notype in endometrial cancer,41 biomarkers including
ER and PR receptor status is still not routinely used
to tailor endometrial cancer treatment. Even in ﬁve
out of six randomised controlled trials regarding hor-
monal treatment, this information is not incorporated
in the patient stratiﬁcation.42 Our prospective multicen-
tre study demonstrates ER/PR status as an independent
factor predicting lymph node metastasis as well as sur-
vival. Such classiﬁcation has recently also been demon-
strated of relevance for targeting systemic therapies in
a metastatic setting.41
This study was not designed to evaluate the role of
lymphadenectomy in the treatment of endometrial can-
cer but oﬀers an alternative approach with “molecular
staging” of patients as a supplement to the well-estab-
lished surgical staging for risk stratiﬁcation. Based on
our presented data we suggest that hormone receptor
status in the future is integrated in randomised clinical
trials of surgical and systemic therapies. ER/PR status
in preoperative biopsies in addition to histopathologic
classiﬁcation improves the identiﬁcation of low- and
high-risk patients. A better preoperative diﬀerentiation
of patients may also allow the allocation of those with
low-risk and localised tumours for treatment at local
hospitals while the more aggressive cancers can be han-
dled adequately at more specialised centres.43
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